Daily treatment with oral glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron results in substantial weight loss in people living with obesity who did not have type 2 diabetes mellitus, according to results from a phase III, multinational, randomised double-blind trial of the once-daily pill.
#ukpharmacy #weightlossdrugs
No comments:
Post a Comment